Back to News
Market Impact: 0.4
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
Source: PR Newswire
M&A & RestructuringHealthcare & BiotechProduct Launches
PTC Therapeutics completed its previously announced acquisition of Sangamo Therapeutics' ST-920, a BLA-stage, one-time therapy candidate. Completion of the biologics license application submission is expected in Q4 2026, adding a late-stage asset to PTC's rare-disease pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
PTCT0.65
SGMOQ0.45
More News
- Paramount agrees invest $1.5 billion in domestic movies and create a board for editorial independence at CNN, CBS as part of deal for Warner Bros.
- Paramount and state AGs will settle lawsuit, allowing Warner Bros. merger to proceed, reports say
- Paramount Set to Settle Lawsuits, Clearing Way for Warner Bros. Deal
- Paramount settles with US states in step towards merger with Warner Bros
- Paramount settles lawsuit blocking $110 billion Warner Bros. merger
- GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?